AXSM (Axsome Therapeutics) Tariff Resilience Score: 6/10 (As of Jun. 27, 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $241.67
GF Value $220.41
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Tariff Resilience Score?

Axsome Therapeutics AXSM +1.83% 52 Tariff Resilience Score is 6 as of Jun. 27, 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,378 Biotechnology companies, Axsome Therapeutics ranks better than 75.98% on this metric.

Axsome Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Axsome Therapeutics has Axsome Therapeutics, a biopharmaceutical company, faces moderate tariff exposure. While its supply chain includes international components, the industry often benefits from tariff exemptions. The company can leverage alternative suppliers if needed.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Axsome Therapeutics might have Average Resilient.

Axsome Therapeutics  (NAS:AXSM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Axsome Therapeutics Tariff Resilience Score Related Terms

AXSM vs IONS, EXEL, MDGL: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Tariff Resilience Score falls into.


AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Axsome Therapeutics (AXSM) has a Tariff Resilience Score of 6 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Axsome Therapeutics ranks #331 out of 1378 companies in the Biotechnology industry, placing it in the top 24%.
Is Axsome Therapeutics' Tariff Resilience Score too high?
Axsome Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Axsome Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Axsome Therapeutics ranks #331 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Tariff Resilience Score compare to IONS and EXEL?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #331 out of 1378 companies for Tariff Resilience Score. This places Axsome Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Axsome Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axsome Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Tariff Resilience Score is 6 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • Tariff Resilience Score: 6
  • GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#331 of 1378)

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$241.67
Price
$220.41
GF Value